Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 4

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  DNA VACCINE
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1

DNA vaccines: are they still just a powerful tool for the future?

100%
Belakova J., Horynova M., Krupka M., Weigl E., Raska M.
|
|
issue 6
387-398
EN
Vaccination is historically one of the most successful strategies for the prevention of infectious diseases. For safety reasons, modern vaccinology tends toward the usage of inactivated or attenuated microorganisms and uses predominantly subunit vaccines. The antigens need to be clearly defined, pure, stable, appropriately composed, and properly presented to the immune system of the host. Differing ratios of various proportions between specific CD4+ and CD8+ T cell responses are essential for conferring the required protection in the case of individual vaccines. To stimulate both CD4+ and CD8+ T cells, the antigens must be processed and presented to both antigen-presentation pathways, MHC I and MHC II. Protein antigens delivered by vaccination are processed as extracellular antigens. However, extracellularly delivered antigen can be directed towards intracellular presentation pathways in conjugation with molecules involved in antigen cross-presentation, e.g. heat shock proteins, or by genomic-DNA vaccination. In this overview, current knowledge of the host immune response to DNA vaccines is summarized in the introduction. The subsequent sections discuss techniques for enhancing DNA vaccine efficacy, such as DNA delivery to specific tissues, delivery of DNA to the cell cytoplasm or nucleus, and enhancement of the immune response using molecular adjuvants. Finally, the prospects of DNA vaccination and ongoing clinical trials with various DNA vaccines are discussed.
2

The new approaches in the area of vaccines development and administer

80%
Kapusta J.
Biotechnologia
|
1999
|
issue 3
94-105
EN
Overviews of current vaccine development in respects to the idea of elaborate vaccines simple to handling and administer. The progress made recently in technologies concerning adjuvants, antigen formulation and vaccine delivery systems has been summarized. Special attention has been focused on mucosal way of vaccine application and orally induced immunity as well newest achievements in the technology using plant as vaccine carriers.
3

Current status and future perspectives of DNA vaccine delivery by attenuated intracellular bacteria

80%
Dietrich G.
Archivum Immunologiae et Therapiae Experimentalis
|
2000
|
vol. 48
|
issue 3
177-182
EN
Vaccination by intradermal or intramuscular injection of antigen-encoding plasmid-DNA elicits strong cellular and humoral immune responses. Professional antigen presenting cells (APC) seem to induce these responses, making it, therefore, desirable to deliver the plasmid molecules directly to these cells. The exploitation of attenuated intracellular bacteria as DNA delivery vehicles makes the direct targeting of DNA vaccine vectors to professional APC feasible.
4

DNA Tumor Vaccines

70%
Wlazlo A. P., Ertl H. C. J.
Archivum Immunologiae et Therapiae Experimentalis
|
2001
|
vol. 49
|
issue 1
1-12
EN
A new generation of vaccines are being developed to induce immune responses that fight off infectious agents, or erradicate cancerous cells. The new vaccines are based on a plasmid vector, which in transfected mammalian cells cause constitutive high-level expression of the target antigen. Expression of the target antigen, in turn, can induce a full-range of immunologic responses, including cell-mediated killing, cell-mediated cytokine release and the production of antigen-specific antibodies. Through molecular techniques, these nucleic acid vaccines can enhanced to increase target antigen expression and faciliatate antigen presentation. Additionally, genetic adjuvants expressed simultaneously with the target antigens can induce the immune responses to disease-associated antigens. The ease with which these genetic vaccines can be generated and the potency of their ability to generate immune-mediated responses make them highly effective, which creates hope for developing effective treatment and prevention of various diseases, most notably cancer.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.